Oncoinvent AS is developing therapeutics to combat various cancers. Immunotargeting of tumor cells and/or delivery of tumour-cell killing doses of radiation are the main mechanisms of the products of Oncoinvent AS.
Oncoinvent’s lead product candidate, Radspherin®, is a new alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. Radspherin® has in animal models been shown to cause a reduction in tumour cell growth and a significant increased survival. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynaecological malignancies. A successful development of Radspherin® will present a novel treatment modality for a group of patients with poor prognosis.
Radspherin® is composed of radioactive spheres for injection. The product is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for regional administration. The therapeutic goal is to treat cancer metastasis of intracavitary surfaces and liquid volumes without harmful radiation doses to deeper regions of organs and tissues.